Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Tenet Healthcare Corporation

THC
Healthcare · Medical Care Facilities

Tenet Healthcare Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

The sharpest disagreement: the price moved +60.2% in a year while annual EPS moved −52.6% — the difference is re-rating, and re-rating has to be repaid with earnings.

The price is in a confirmed uptrend (3 weeks in). Underneath, the last four quarters read improving — profit +46.8% year on year, and 103% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.

Stage
Mixed
fundamental trajectory, 12 quarters
Price
$253
+60.2% 1Y
P/E
9.8×
of its own 4-year range
Revenue (Mar 26)
$5.4 B
+2.9% YoY
Profit (Mar 26)
$0.9 B
+46.8% YoY
Operating margin
23.3%
+6.3 pp YoY
ROE
37%
FY25
ROIC
16.7%
vs WACC 8.7% → +8.0 pp
Cash conversion
103%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Tenet Healthcare Corporation trades at $253, in a confirmed uptrend and 3 weeks into that stage. That is +26.1% against its own 200-day average. It sits at 98% of a 52-week range of $162 to $255. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 3 straight weeks.

Today the stock is in a confirmed uptrend — week 3 of stage 2. At $253 it trades +26.1% versus its 200-day average and sits at 98% of its 52-week range ($162–$255).

Aug 26: $253 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+26.1% versus the 200-day line, week 3 of stage 2
Price50-day avg200-day avg
S2S1S2S1$271$212$154$95.5$37.0$$253$201Jul 23Apr 24Jan 25Oct 25Aug 26
S2S1S2S1$271$212$154$95.5$37.0$$253$201Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +777% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Tenet Healthcare Corporation trades at 9.8× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 9.8× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 9.8× vs a null× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 4.3-year window; loss-period spikes above 19× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
against too little history to rank
P/EEPS (TTM) (quarterly)
20.7×$34.816.1×$26.111.5×$17.46.9×$8.72.4×$0.0×$13.17×$19Apr 22Apr 23May 24Jul 25Aug 26
20.7×$34.816.1×$26.111.5×$17.46.9×$8.72.4×$0.0×$13.17×$19Apr 22May 24Aug 26
PEG 1.54 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters; values above 6 pinned at the top.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
6.4×4.9×3.4×1.8×0.3××1.54×Sep 21Sep 22Dec 23Mar 25Jun 26
6.4×4.9×3.4×1.8×0.3××1.54×Sep 21Dec 23Jun 26
P/E
9.8×
too little history to rank
PEG
0.99
as reported

🚨 Why the multiple sits where it does: over the past year annual EPS moved −52.6% against a +60.2% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 3y, of the +50.4%/yr price move, ~+61.7%/yr came from earnings growth and ~−11.3 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Tenet Healthcare Corporation reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 14.4% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +3.0% in FY25, profit −41.6% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn. Turnaround-year spikes shown pinned (▲).
Revenue YoYProfit YoYEPS YoY
6.7%328%4.5%225%2.3%123%0.0%20%−2.2%−83%%%3%−41.6%FY21FY23FY25
6.7%328%4.5%225%2.3%123%0.0%20%−2.2%−83%%%3%−41.6%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue accelerating, profit accelerating
RevenueProfitEPS
7.2%328%4.7%226%2.3%123%−0.1%21%−2.6%−82%%%4.5%12.8%27.2%Jun 23Sep 24Mar 26
7.2%328%4.7%226%2.3%123%−0.1%21%−2.6%−82%%%4.5%12.8%27.2%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
15%13%12%10%8.7%%14.4%Jun 23Dec 23Sep 24Jun 25Mar 26
15%13%12%10%8.7%%14.4%Jun 23Sep 24Mar 26
Revenue growth
Steady high
latest +4.5% · span −1.9% to +6.5%
Profit growth
Rising
latest +12.8% · span −42.0% to +246.5%
EPS growth
Rising
latest +27.2% · span −53.3% to +620.8%
ROCE
Stuck low
latest 14.4% · span 9.1%–14.4%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+3.0%+3.2%
Profit−41.6%+33.3%
EPS−52.6%+59.9%
Stock price+60.2%+50.4%+29.8%+24.9%
Revenue YoY (Mar 26)
+2.9%
latest quarter vs a year ago
Profit YoY (Mar 26)
+46.8%
latest quarter vs a year ago
Revenue 10y
2.0%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

64.4/100 — rank 2 of 30 in Medical Care Facilities · 58% evidence confidence

Tenet Healthcare Corporation scores 64.4 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 2. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 23.7 + 16.5 + 11.1 + 13.1 = 64.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Tenet Healthcare Corporation reported $5.4 B of revenue in the Mar 26 quarter, +2.9% year on year. That is the 4th straight quarter of year-on-year growth. Over 4 years it has compounded at 2.0% a year. The last full year, FY25, came in at $21.3 B. The last four reported quarters add to $21.5 B.

FY25 revenue came in at $21.3 B (+3.0% on the year), capping 4 years at 2.0% compound. The latest quarter (Mar 26) printed $5.4 B, +2.9% year on year — the 4th consecutive quarter of year-over-year growth.

FY25 revenue $21.3 B (+3.0% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
2.0% a year over 4 years
RevenueYoY growth
236.7%174.5%122.3%5.80.0%0.0−2.2%$ B%$21B3%FY21FY23FY25
236.7%174.5%122.3%5.80.0%0.0−2.2%$ B%$21B3%FY21FY23FY25
Mar 26: $5.4 B (+2.9% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
4th straight quarter of growth
Revenue (quarterly)YoY growth
6.010%4.55.9%3.01.6%1.5−2.8%0.0−7.1%$ B%$5B2.9%Jun 23Sep 24Mar 26
6.010%4.55.9%3.01.6%1.5−2.8%0.0−7.1%$ B%$5B2.9%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +4.5% growth against the decade's 2.0% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +4.5% over the last 4 quarters against +1.3%/yr over the last 8 — accelerating; TTM profit +12.8% vs −11.1%/yr — accelerating.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Tenet Healthcare Corporation's operating margin is 23.3% in the Mar 26 quarter, +6.3 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 10.9% to 27.6%. The current quarter sits inside that band.

The latest quarter's operating margin is 23.3%, +6.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 10.9%–27.6%.

Why the margin moved: operating margin went +6.3 pp year on year while gross margin went −0.6 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: 15.2% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 10.9–27.6% band over 5 years
operating marginYoY change (pp)
29%19%24%10%19%2.1%14%−6.3%9.6%−15%%%15.2%−12.4%FY21FY23FY25
29%19%24%10%19%2.1%14%−6.3%9.6%−15%%%15.2%−12.4%FY21FY23FY25
Mar 26: 23.3% operating margin (+6.3 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
64%56%50%30%35%3.0%21%−24%6.3%−50%%%23.3%6.3%Jun 23Sep 24Mar 26
64%56%50%30%35%3.0%21%−24%6.3%−50%%%23.3%6.3%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Tenet Healthcare Corporation earned $0.9 B of net profit in the Mar 26 quarter, +46.8% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $2.4 B. The 4-year compound rate is 12.5%. That is 16.9% of the quarter's revenue. The same quarter a year earlier earned $0.6 B.

Mar 26 profit was $0.9 B, +46.8% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $2.4 B (−41.6%), and the 4-year compound rate is 12.5%.

FY25 profit $2.4 B (−41.6% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
12.5% a year over 4 years
Net profitYoY growth
4.4230%3.3157%2.284%1.111%0.0−62%$ B%$2B−41.6%FY21FY23FY25
4.4230%3.3157%2.284%1.111%0.0−62%$ B%$2B−41.6%FY21FY23FY25
Mar 26: $0.9 B (+46.8% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
2nd straight quarter of growth
Net profit (quarterly)YoY growth
2.5737%1.9519%1.3302%0.684%0.0−133%$ B%$1B46.8%Jun 23Sep 24Mar 26
2.5737%1.9519%1.3302%0.684%0.0−133%$ B%$1B46.8%Jun 23Sep 24Mar 26

Why profit moved: revenue contributed +2.9% and the margin +6.3 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +13.2% vs revenue +4.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 103% of Tenet Healthcare Corporation's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $3.5 B of operating cash against $2.4 B of profit. After $1.0 B of capital spending, $2.5 B was left as free cash.

FY25: operating cash of $3.5 B against reported profit of $2.4 B, leaving free cash of $2.5 B after $1.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 103% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $3.5 B vs profit $2.4 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
103% of 3-year profit arrived as cash
Operating cashNet profitFree cash
4.43.32.21.10.0$ B$4B$2B$3BFY21FY23FY25
4.43.32.21.10.0$ B$4B$2B$3BFY21FY23FY25
Jun 26: operating cash $0.6 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
1.8204%1.2134%0.764%0.1−7.0%−0.5−77%$ B%$1B180%Sep 23Dec 24Jun 26
1.8204%1.2134%0.764%0.1−7.0%−0.5−77%$ B%$1B180%Sep 23Dec 24Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Tenet Healthcare Corporation does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $3.0 B over the last 3 years. Averaged over those years that is 4.7% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $3.0 B over the last 3 fiscal years.

FY25: capex $1.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
1.10.80.50.30.0$ B$1BFY21FY23FY25
1.10.80.50.30.0$ B$1BFY21FY23FY25
Jun 26: capex $0.2 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.41.60.31.00.20.40.1−0.20.0−0.8$ B$ B$0B$0BSep 23Dec 24Jun 26
0.41.60.31.00.20.40.1−0.20.0−0.8$ B$ B$0B$0BSep 23Dec 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Tenet Healthcare Corporation earns a ROE of 26% in FY25. That is up from a trough of 22% in FY22. Return on invested capital clears the cost of that capital by +8.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.1% net margin on 0.72× asset turns.

FY25 ROE is 26%, recovered from a FY22 trough of 22% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 11.1% net margin × 0.72× asset turns × 3.31× balance-sheet leverage ≈ 26.5% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 16.7% − 8.7% = a +8.0 pp spread. The 8.7% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.

FY25: ROE 26% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 8.7% cost of capital used on this page.
the climb back from FY22's 22%
ROEROIC (annual)WACC
51%39%28%17%5.6%%26.4%14.4%FY21FY23FY25
51%39%28%17%5.6%%26.4%14.4%FY21FY23FY25
Jun 26: ROIC 18.4% (TTM) vs WACC 8.7% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
69%52%36%20%4.3%%18.4%37%Sep 23Dec 24Jun 26
69%52%36%20%4.3%%18.4%37%Sep 23Dec 24Jun 26
11 · Dividend

Dividend

Tenet Healthcare Corporation pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Tenet Healthcare Corporation does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Tenet Healthcare Corporation carries total debt of $13.3 B against shareholder equity of $8.7 B as of Jun 26, a debt-to-equity of 1.52. On the annual view that ratio went from 3.67 in FY21 to 1.47 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of $13.3 B against shareholder equity of $8.7 B — a debt-to-equity of 1.52. On the annual view, debt-to-equity went from 3.67 (FY21) to 1.47 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $13.2 B at 1.47× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
173.8×133.2×8.52.6×4.21.9×0.01.3×$ B×$13B1.47×FY21FY23FY25
173.8×133.2×8.52.6×4.21.9×0.01.3×$ B×$13B1.47×FY21FY23FY25
Jun 26: debt $13.3 B, debt-to-equity 1.52 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
163.0×122.6×8.12.2×4.11.8×0.01.4×$ B×$13B1.52×Sep 23Dec 24Jun 26
163.0×122.6×8.12.2×4.11.8×0.01.4×$ B×$13B1.52×Sep 23Dec 24Jun 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

3.8% of Tenet Healthcare Corporation's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 3.8% of the float is sold short, and at typical trading volumes it would take about 2.2 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
3.8%
of the tradable float
Days to cover
2.2
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Tenet Healthcare Corporation: the Z-score reads 1.96. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 1.96 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 1.96.

15 · Related companies · Medical Care Facilities
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1AMN Healthcare Services, Inc.AMN 64.5/100Thin evidence · provisional58% evidence LEADER 26.0/35 Revenue 19.8% · PAT — · OPM change 6.7 pp 62% evidence 13.2/25 ROCE 6.9% · OPM 8.5% 76% evidence 9.2/20 P/E 30.7× · PEG — 15% evidence 16.1/20 RS sector 15.6% · RS bench 36.1% · 1Y 92.9%12 of 12 weeks ahead 70% evidence
Exact sum: 26 + 13.2 + 9.2 + 16.1 = 64.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
2Tenet Healthcare Corporationthis pageTHC 64.4/100Thin evidence · provisional58% evidence TURNING 23.7/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence 16.5/25 ROCE 5.8% · OPM 23.2% 76% evidence 11.1/20 P/E 7.2× · PEG — 15% evidence 13.1/20 RS sector -5.5% · RS bench 13.7% · 1Y 53%3 of 12 weeks ahead 100% evidence
Exact sum: 23.7 + 16.5 + 11.1 + 13.1 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Concentra Group Holdings Parent, Inc.CON 60.1/100Mixed-positive evidence71% evidence BREAKING OUT 19.8/35 Revenue 15.5% · PAT 12.9% · OPM change 0.8 pp 83% evidence 14.8/25 ROCE 3.8% · OPM 16.8% 76% evidence 10.2/20 P/E 15.4× · PEG — 15% evidence 15.3/20 RS sector 0.9% · RS bench 19.9% · 1Y 43.9%9 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 14.8 + 10.2 + 15.3 = 60.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4PACS Group, Inc.PACS 58.7/100Thin evidence · provisional56% evidence BREAKING OUT 21.9/35 Revenue — · PAT — · OPM change 4.7 pp 39% evidence 13.3/25 ROCE 5.2% · OPM 8.5% 76% evidence 9.1/20 P/E 31.5× · PEG — 15% evidence 14.4/20 RS sector 15% · RS bench 34% · 1Y 302.2%7 of 12 weeks ahead 100% evidence
Exact sum: 21.9 + 13.3 + 9.1 + 14.4 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5Encompass Health CorporationEHC 55.8/100Mixed-positive evidence81% evidence BASING 20.6/35 Revenue 10.1% · PAT 21% · OPM change 0.7 pp 83% evidence 15.8/25 ROCE 4.9% · OPM 19% 76% evidence 14.4/20 P/E 16.1× · PEG 0.68 65% evidence 5.0/20 RS sector -25.7% · RS bench -10% · 1Y -6%1 of 12 weeks ahead 100% evidence
Exact sum: 20.6 + 15.8 + 14.4 + 5 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Chemed CorporationCHE 55.8/100Thin evidence · provisional58% evidence BREAKING OUT 18.0/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence 15.7/25 ROCE 6.6% · OPM 12.9% 76% evidence 9.5/20 P/E 23.4× · PEG — 15% evidence 12.6/20 RS sector -8.7% · RS bench 9.9% · 1Y 24%7 of 12 weeks ahead 100% evidence
Exact sum: 18 + 15.7 + 9.5 + 12.6 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7Fresenius Medical Care AGFMS 55.0/100Mixed-positive evidence81% evidence TURNING 21.6/35 Revenue -0.7% · PAT 43.7% · OPM change 1.5 pp 83% evidence 11.4/25 ROCE 2.1% · OPM 11.7% 76% evidence 15.8/20 P/E 11.9× · PEG 0.22 65% evidence 6.2/20 RS sector -25.4% · RS bench -9.8% · 1Y -0.2%1 of 12 weeks ahead 100% evidence
Exact sum: 21.6 + 11.4 + 15.8 + 6.2 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Addus HomeCare CorporationADUS 54.4/100Mixed-positive evidence81% evidence BREAKING OUT 21.2/35 Revenue 19.5% · PAT 26.6% · OPM change 0.4 pp 83% evidence 12.3/25 ROCE 2.7% · OPM 9.4% 76% evidence 13.7/20 P/E 17.3× · PEG 0.78 65% evidence 7.2/20 RS sector -21.4% · RS bench -4.9% · 1Y 3.1%5 of 12 weeks ahead 100% evidence
Exact sum: 21.2 + 12.3 + 13.7 + 7.2 = 54.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9LifeStance Health Group, Inc.LFST 53.3/100Mixed-positive evidence64% evidence BREAKING OUT 22.1/35 Revenue 16.4% · PAT — · OPM change 5 pp 62% evidence 5.8/25 ROCE 1.2% · OPM 5.5% 76% evidence 8.5/20 P/E 106.2× · PEG — 15% evidence 16.9/20 RS sector 10.2% · RS bench 29.9% · 1Y 134.8%9 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 5.8 + 8.5 + 16.9 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10agilon health, inc.AGL 53.2/100Mixed-positive evidence61% evidence LEADER 18.4/35 Revenue -2.8% · PAT — · OPM change 1.7 pp 62% evidence 4.8/25 ROCE 1% · OPM 0.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 20.0/20 RS sector 87% · RS bench 109.7% · 1Y 334%12 of 12 weeks ahead 100% evidence
Exact sum: 18.4 + 4.8 + 10 + 20 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Healthcare Services Group, Inc.HCSG 53.2/100Thin evidence · provisional52% evidence FADING 22.9/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence 10.6/25 ROCE 3.6% · OPM 7.3% 76% evidence 10.4/20 P/E 14.3× · PEG — 15% evidence 9.3/20 RS sector -10.3% · RS bench 6.7% · 1Y 60.9%6 of 12 weeks ahead 70% evidence
Exact sum: 22.9 + 10.6 + 10.4 + 9.3 = 53.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12DaVita Inc.DVA 53.0/100Mixed-positive evidence81% evidence LEADER 16.1/35 Revenue 6.7% · PAT -6.9% · OPM change 0.5 pp 83% evidence 13.7/25 ROCE 3.3% · OPM 14.1% 76% evidence 8.0/20 P/E 14.3× · PEG 2.08 65% evidence 15.2/20 RS sector 13.4% · RS bench 33.4% · 1Y 76.1%12 of 12 weeks ahead 100% evidence
Exact sum: 16.1 + 13.7 + 8 + 15.2 = 53 · Decision use: Price leads the evidence: RS versus the benchmark is 33.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
13Acadia Healthcare Company, Inc.ACHC 49.1/100Thin evidence · provisional58% evidence BREAKING OUT 14.7/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 7.5/25 ROCE 1.1% · OPM 5.8% 76% evidence 9.6/20 P/E 21.2× · PEG — 15% evidence 17.3/20 RS sector 7.7% · RS bench 27.7% · 1Y 64.6%6 of 12 weeks ahead 100% evidence
Exact sum: 14.7 + 7.5 + 9.6 + 17.3 = 49.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14National HealthCare CorporationNHC 47.5/100Mixed-negative evidence81% evidence LEADER 16.5/35 Revenue 10.3% · PAT 16.7% · OPM change 0.2 pp 83% evidence 10.2/25 ROCE 2.5% · OPM 8.4% 76% evidence 9.9/20 P/E 20.3× · PEG 1.48 65% evidence 10.9/20 RS sector 1.4% · RS bench 19.5% · 1Y 107.4%10 of 12 weeks ahead 100% evidence
Exact sum: 16.5 + 10.2 + 9.9 + 10.9 = 47.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Guardian Pharmacy Services, Inc.GRDN 46.8/100Mixed-negative evidence64% evidence TURNING 17.2/35 Revenue 13.6% · PAT — · OPM change 1.4 pp 62% evidence 12.6/25 ROCE 7.8% · OPM 5.3% 76% evidence 8.7/20 P/E 45.4× · PEG — 15% evidence 8.3/20 RS sector -6.7% · RS bench 10.7% · 1Y 103%6 of 12 weeks ahead 100% evidence
Exact sum: 17.2 + 12.6 + 8.7 + 8.3 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16HCA Healthcare, Inc.HCA 44.8/100Thin evidence · provisional58% evidence BASING 16.2/35 Revenue — · PAT — · OPM change -0.6 pp 45% evidence 16.4/25 ROCE 6.9% · OPM 15% 76% evidence 10.7/20 P/E 13.1× · PEG — 15% evidence 1.5/20 RS sector -33.7% · RS bench -19.8% · 1Y 5%0 of 12 weeks ahead 100% evidence
Exact sum: 16.2 + 16.4 + 10.7 + 1.5 = 44.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17The Pennant Group, Inc.PNTG 44.7/100Mixed-negative evidence75% evidence FADING 20.4/35 Revenue 36.6% · PAT 20.7% · OPM change 0.1 pp 83% evidence 9.2/25 ROCE 2.3% · OPM 6.1% 76% evidence 4.0/20 P/E 35.9× · PEG 3.03 65% evidence 11.1/20 RS sector -3.7% · RS bench 14.3% · 1Y 48.5%6 of 12 weeks ahead 70% evidence
Exact sum: 20.4 + 9.2 + 4 + 11.1 = 44.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Aveanna Healthcare Holdings Inc.AVAH 44.5/100Thin evidence · provisional58% evidence BREAKING OUT 11.5/35 Revenue — · PAT — · OPM change -2.9 pp 45% evidence 11.8/25 ROCE 4.8% · OPM 10.7% 76% evidence 11.4/20 P/E 5.4× · PEG — 15% evidence 9.8/20 RS sector -14.2% · RS bench 3.6% · 1Y 52.4%7 of 12 weeks ahead 100% evidence
Exact sum: 11.5 + 11.8 + 11.4 + 9.8 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19Universal Health Services, Inc.UHS 44.3/100Thin evidence · provisional58% evidence BASING 16.4/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 14.1/25 ROCE 4.1% · OPM 11.2% 76% evidence 11.3/20 P/E 6.1× · PEG — 15% evidence 2.5/20 RS sector -35.5% · RS bench -21.5% · 1Y -2.6%0 of 12 weeks ahead 100% evidence
Exact sum: 16.4 + 14.1 + 11.3 + 2.5 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
20Option Care Health, Inc.OPCH 43.4/100Thin evidence · provisional58% evidence TURNING 17.0/35 Revenue — · PAT — · OPM change -0.5 pp 45% evidence 11.3/25 ROCE 3.3% · OPM 5.4% 76% evidence 10.1/20 P/E 15.8× · PEG — 15% evidence 5.0/20 RS sector -37.2% · RS bench -23.5% · 1Y -16%2 of 12 weeks ahead 100% evidence
Exact sum: 17 + 11.3 + 10.1 + 5 = 43.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21Pediatrix Medical Group, Inc.MD 43.3/100Mixed-negative evidence74% evidence FADING 17.5/35 Revenue -2.2% · PAT — · OPM change 1.7 pp 62% evidence 10.2/25 ROCE 2.5% · OPM 8.7% 76% evidence 9.9/20 P/E 10.4× · PEG 1.7 65% evidence 5.7/20 RS sector -11.9% · RS bench 5.1% · 1Y 72.4%7 of 12 weeks ahead 100% evidence
Exact sum: 17.5 + 10.2 + 9.9 + 5.7 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22The Ensign Group, Inc.ENSG 42.2/100Thin evidence · provisional58% evidence BASING 17.7/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence 12.2/25 ROCE 2.7% · OPM 9% 76% evidence 9.3/20 P/E 25.1× · PEG — 15% evidence 3.0/20 RS sector -27.5% · RS bench -12.6% · 1Y 9.6%0 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 12.2 + 9.3 + 3 = 42.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Select Medical Holdings CorporationSEM 40.7/100Mixed-negative evidence75% evidence 11.1/35 Revenue 5.8% · PAT -20% · OPM change -1.4 pp 83% evidence 9.7/25 ROCE 2% · OPM 6.9% 76% evidence 13.1/20 P/E 15.4× · PEG 0.93 65% evidence 6.8/20 RS sector -22.8% · RS bench 1.5% · 1Y 9%0 of 7 weeks ahead to 2026-07-02 70% evidence
Exact sum: 11.1 + 9.7 + 13.1 + 6.8 = 40.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
24InnovAge Holding Corp.INNV 39.7/100Thin evidence · provisional58% evidence BREAKING OUT 10.8/35 Revenue 14.2% · PAT — · OPM change -6.8 pp 62% evidence 3.6/25 ROCE -8.8% · OPM -11.5% 76% evidence 8.6/20 P/E 103.8× · PEG — 15% evidence 16.7/20 RS sector 20% · RS bench 39.9% · 1Y 227.8%7 of 12 weeks ahead 70% evidence
Exact sum: 10.8 + 3.6 + 8.6 + 16.7 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25Brookdale Senior Living Inc.BKD 39.3/100Mixed-negative evidence61% evidence TURNING 17.0/35 Revenue -0.4% · PAT — · OPM change 3.2 pp 62% evidence 5.0/25 ROCE 0.9% · OPM 6.8% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 7.3/20 RS sector -10.3% · RS bench 6.1% · 1Y 97.4%2 of 12 weeks ahead 100% evidence
Exact sum: 17 + 5 + 10 + 7.3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Ardent Health, Inc.ARDT 39.2/100Mixed-negative evidence65% evidence TURNING 14.3/35 Revenue 6.7% · PAT -26.8% · OPM change 0.6 pp 83% evidence 8.7/25 ROCE 1.9% · OPM 5.1% 76% evidence 11.0/20 P/E 9× · PEG — 15% evidence 5.2/20 RS sector -24.1% · RS bench -7.7% · 1Y -9.6%2 of 12 weeks ahead 70% evidence
Exact sum: 14.3 + 8.7 + 11 + 5.2 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27Astrana Health, Inc.ASTH 37.9/100Mixed-negative evidence81% evidence FADING 14.2/35 Revenue 56.8% · PAT -20.5% · OPM change -0.3 pp 83% evidence 7.3/25 ROCE 2.2% · OPM 3% 76% evidence 10.5/20 P/E 40.2× · PEG 1.17 65% evidence 5.9/20 RS sector -10.4% · RS bench 6.4% · 1Y 27%10 of 12 weeks ahead 100% evidence
Exact sum: 14.2 + 7.3 + 10.5 + 5.9 = 37.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Surgery Partners, Inc.SGRY 36.7/100Mixed-negative evidence61% evidence FADING 13.9/35 Revenue 5.4% · PAT — · OPM change 0.1 pp 62% evidence 7.2/25 ROCE 0.9% · OPM 8.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 5.6/20 RS sector -31% · RS bench -15.8% · 1Y -33.8%7 of 12 weeks ahead 100% evidence
Exact sum: 13.9 + 7.2 + 10 + 5.6 = 36.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
29Sonida Senior Living, Inc.SNDA 34.2/100Adverse evidence64% evidence FADING 13.0/35 Revenue 25.5% · PAT — · OPM change -20.5 pp 62% evidence 3.8/25 ROCE -1.9% · OPM -23.6% 76% evidence 11.5/20 P/E 1.9× · PEG — 15% evidence 5.9/20 RS sector -11.4% · RS bench 5.4% · 1Y 58.1%5 of 12 weeks ahead 100% evidence
Exact sum: 13 + 3.8 + 11.5 + 5.9 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
30COMPASS Pathways plcCMPS 48.3/100Thin evidence · provisional47% evidence LEADER 19.8/35 Revenue — · PAT — · OPM change — 33% evidence 5.0/25 ROCE -12.9% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 13.5/20 RS sector 18.2% · RS bench 37.9% · 1Y 168.8%12 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 5 + 10 + 13.5 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Tenet Healthcare Corporation's stock price today?

Tenet Healthcare Corporation trades at $253, +60.2% over the past year. The company is valued at $20.0 B. The stock sits at 98% of its 52-week range of $162–$255, +26.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 3 weeks in. — as of 5 August 2026.

What were Tenet Healthcare Corporation's latest quarterly results?

Tenet Healthcare Corporation reported revenue of $5.4 B and net profit of $0.9 B for the Mar 26 quarter. Revenue rose 2.9% and profit rose 46.8% year on year. Earnings per share were $8.01. The operating margin was 23.3%, 6.3 pp higher than a year earlier. — as of 5 August 2026.

What is Tenet Healthcare Corporation's revenue?

Tenet Healthcare Corporation reported revenue of $5.4 B in the Mar 26 quarter, +2.9% year on year. For the full FY25 fiscal year, revenue was $21.3 B (+3.0%). Over the last 4 years revenue compounded at 2.0% a year. — as of 5 August 2026.

What is Tenet Healthcare Corporation's profit?

Tenet Healthcare Corporation earned $0.9 B of net profit in the Mar 26 quarter, +46.8% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $2.4 B. The operating margin ran 23.3% in the latest quarter. — as of 5 August 2026.

What is Tenet Healthcare Corporation's market cap?

Tenet Healthcare Corporation's market capitalisation is $20.0 B at a stock price of $253. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

Does Tenet Healthcare Corporation pay a dividend?

No — Tenet Healthcare Corporation has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

Is Tenet Healthcare Corporation growing?

Yes — Tenet Healthcare Corporation is growing: latest-quarter revenue +2.9% year on year, profit +46.8%, and the margin +6.3 pp at 23.3%. The 4-year compound rates are 2.0% (revenue) and 12.5% (profit). The earnings engine currently reads: improving — as of 5 August 2026.

How is Tenet Healthcare Corporation performing?

Tenet Healthcare Corporation is in a confirmed uptrend, 3 weeks in. Its latest quarter's revenue rose 2.9% and profit rose 46.8% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Tenet Healthcare Corporation in?

Mixed — the growth curves are steadily positive, but ROCE at 14.4% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +4.5% latest, profit growth +12.8% latest, eps growth +27.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Tenet Healthcare Corporation in an uptrend?

Yes — the price is in a confirmed uptrend (week 3 of stage 2), trading +26.1% versus its 200-day average and at 98% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Tenet Healthcare Corporation beating the market?

On recent form, yes — Tenet Healthcare Corporation has been ahead of the S&P 500 on a trailing-13-week view for 3 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +777% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.

Will Tenet Healthcare Corporation's stock price go up?

This page publishes no price forecast for Tenet Healthcare Corporation. What it measures instead: the stock price is $253, the price is in a confirmed uptrend 3 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Tenet Healthcare Corporation?

Somewhat — short interest is 3.8% of Tenet Healthcare Corporation's tradable float, about 2.2 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does Tenet Healthcare Corporation have too much debt?

It carries real leverage — Tenet Healthcare Corporation's debt-to-equity is 1.52. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.

What is Tenet Healthcare Corporation's capex?

Tenet Healthcare Corporation spent $3.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.0 B. — as of 5 August 2026.

What is Tenet Healthcare Corporation's cash flow?

Tenet Healthcare Corporation generated $3.5 B of operating cash flow in FY25 and $2.5 B of free cash flow after $1.0 B of capital spending. Reported profit that year was $2.4 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is Tenet Healthcare Corporation's profit real cash?

Yes — over the last 3 fiscal years, 103% of Tenet Healthcare Corporation's reported profit arrived as operating cash. In FY25, operating cash was $3.5 B against reported profit of $2.4 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is Tenet Healthcare Corporation?

On the balance sheet, the Z-score reads 1.96 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.

Where is Tenet Healthcare Corporation in its business cycle?

Tenet Healthcare Corporation's FY25 operating margin was 15.2%, against a 5-year band of 10.9%–27.6%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 23.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Tenet Healthcare Corporation story?

The sharpest disagreement: the price moved +60.2% in a year while annual EPS moved −52.6% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Tenet Healthcare Corporation a stock worth studying right now?

This is not investment advice. The machine read: Tenet Healthcare Corporation's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI